Bone damage in type 2 diabetes mellitus

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 11, 2014, Pages 1151-1157

  Carnevale, V ^a   Romagnoli, E ^b   D'Erasmo, L ^b   D'Erasmo, E ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone mineral density; Bone quality; Clinical risk factors; Fractures; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADVANCED GLYCATION END PRODUCT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; EXENDIN 4; FETUIN A; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIRAGLUTIDE; METFORMIN; OSTEOCALCIN; PENTOSIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RETINOL BINDING PROTEIN 4; ROSIGLITAZONE; SCLEROSTIN; SITAGLIPTIN; SULFONYLUREA; TRANSCRIPTION FACTOR RUNX; VILDAGLIPTIN;

ANKYLOSING HYPEROSTOSIS; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE FRAGILITY; BONE INJURY; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIP FRACTURE; HUMAN; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

EID: 84909645591     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.06.013     Document Type: Review

References (69)

1. Carnevale V., Romagnoli E., D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004, 20:196-204.
2. Merlotti D., Gennari L., Dotta F., Lauro D., Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 2010, 20:683-690.
3. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
4. International Osteoporosis Foundation Facts and statistics http://www.iofbonehealth.org/facts-statistics.
5. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:726-1733.
6. Gerber Y., Melton L.J., McNallan S.M., Jiang R., Weston S.A., Roger V.L. Cardiovascular and noncardiovascular disease associations with hip fractures. Am J Med 2013, 126:169. e19-169.e26.
7. Billings L.K., Hsu Y.H., Ackerman R.J., Dupuis J., Voigt B.F., Rasmussen-Torvik L.J., et al. Impact of common variation in bone-related genes on type 2 diabetes and related traits. Diabetes 2012, 61:2176-2186.
8. Schwartz A.V., Vittinghof E., Sellmeyer D.E., Feingold K.R., de Rekeneire N., Strotmeyer E.S., et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008, 31:391-396.
9. Saito M., Kida Y., Kato S., Marumo K. Diabetes, collagen, and bone quality. Curr Osteoporos Rep 2014, 12:181-188.
10. Leslie W.D., Rubin M.R., Schwartz A.V., Kanis J.A. Type 2 diabetes and bone. J Bone Min Res 2012, 27:2231-2237.
11. Ma L., Oei L., Jiang L., Estrada K., Chen H., Wang Z., et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 2012, 27:319-332.
12. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 2007, 18:427-444.
13. Yan W., Li X. Impact of diabetes and its treatment in skeletal diseases. Front Med 2013, 7:81-90.
14. Abdulameer S.A., Sulaiman S.A.S., Hassali M.A.A., Subramanian K., Sahib M.N. Osteoporosis and type 2 diabetes mellitus: what do we know and what we can do?. Patient Prefer Adherence 2012, 6:435-448.
15. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J., et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001, 86:32-38.
16. Ivers R.Q., Cummings R.G., Mitchell P., Peduto A.J. Diabetes and risk of fracture. The Blue Mountains Eye study. Diabetes Care 2001, 24:1198-1203.
17. Nicodemus K.K., Folsom A.R. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001, 24:1192-1197.
18. Bonds D.E., Larson J.C., Schwartz A.V., Strotmeyer E.S., Robbins J., Rodriguez B.L., et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative observational study. J Clin Endocrinol Metab 2006, 91:3404-3410.
19. Janghorbani M., Van Dam R.M., Willett W.C., Hu F.B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007, 166:495-505.
20. Melton L.J., Leibson C.L., Achenbach S.J., Therneau T.M., Koshla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Min Res 2008, 23:1334-1342.
21. Petit M.A., Paudel M.L., Taylor B.C., Hughes J.M., Strotmeyer E.S., Schwrtz A.V., et al. Bone mass and strength in older men with type 2 diabetes: the osteoporotic fractures in men study. J Bone Min Res 2010, 25:285-291.
22. Hothershall E.J., Livingstone S.J., Looker H.C., Ahmaed S.F., Cleland S., Leese G.P., et al. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Min Res 2014, 29:1054-1060.
23. Janghorbani M., Feskanich D., Willet W.C., Hu F. Prospective study of diabetes and risk of hip fracture. The Nurses' Health Study. Diabetes Care 2006, 29:1573-1578.
24. De Liefde I., van der Klift M., de Laet C.E., van Daele P.L., Hofman A., Pols H.A. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005, 16:1713-1720.
25. Schwartz A.V., Sellmeyer D.E., Trotmeyer E.S., Tylavsky F.A., Feingold K.R., Resnick H.E., et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Min Res 2005, 20:596-603.
26. Chung D.J., Choi H.J., Chung Y.S., Lim S.K., Yang S.O., Shin C.S. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes. J Bone Min Metab 2013, 31:161-168.
27. Di Somma C., Rubino M., Faggiano A., Vuolo L., Contaldi P., Tafuri N., et al. Spinal deformity index in patients with type 2 diabetes. Endocrine 2013, 43:651-658.
28. Schwartz A.V., Vittinghof E., Bauer D.C., Hillier T.A., Strotmeyer E.S., Ensrud K.E., et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. J Am Med Assoc 2011, 305:2184-2192.
29. Kanis J.A., Oden A., Johansson H., Borgström F., Ström O., McCloskey E. FRAX and its application to clinical practice. Bone 2009, 44:734-743.
30. Giangregorio L.M., Leslie W.D., Lix L.M., Johansson H., Oden A., Mc Closkey E., et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Min Res 2012, 27:301-308.
31. Carnevale V., Morano S., Fontana A., Annese M.A., Fallarino M., Filardi T., et al. Assessment of fracture risk by the FRAX algorithm in men and women with and without type 2 diabetes mellitus: a cross-sectional study. Diabetes Metab Res Rev 2014, 30:313-322.
32. Hippisley-Cox J., Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture inprimary care in the United Kingdom: prospective open cohortstudy. Brit Med J 2012, 344:e3427. 10.1136/bmj.e3427.
33. Ishii S., Cauley J.A., Crandall C.J., Srikanthan P., Greendale G.A., Huang M.H., et al. Diabetes and femoral neck strength: finding from the hip strength across the menopausal transition study. J Clin Endocrinol Metab 2012, 97:190-197.
34. Hamilton C.J., Jamal S.A., Beck T.J., Khaled A.S., Adachi J.D., Brown J.P., et al. Evidence for impaired skeletal load adaptation among Canadian women with type 2 diabetes mellitus: insight into the BMD and bone fragility paradox. Metabolism 2013, 62:1401-1405.
35. Oei L., Zillikens M.C., Dehghan A., Buitendijk G.H.S., Castano-Betancourt M.C., Estrada K., et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control. Diabetes Care 2013, 36:1619-1628.
36. Burghardt A.J., Issever A.S., Schwartz A.V., Davis K.A., Masharani U., Majumdar S., et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone micro-architecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:5045-5055.
37. Patsch J.M., Burghardt A.J., Yap S.P., Baum T., Schwartz A.V., Joseph G.B., et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Min Res 2013, 28:313-324.
38. Melton L.J., Riggs B.L., Leibson C.L., Achenbach S.J., Camp J.J., Bouxsein M.L., et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008, 93:4804-4809.
39. Romagnoli E., Cipriani C., Nofroni I., Castro C., Angelozzi M., Scarpiello A., et al. "Trabecular bone score" (TBS): an in direct measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 2013, 53:154-159.
40. Leslie W.D., Aubry-Rozier B., Lami O., Hans D. TBS (Trabecular Bone Score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013, 98:602-609. Manitoba Bone Density Program.
41. Tang S.Y., Vashishth D. The relative contributions of non-enzymatic glycation and cortical porosity on the fracture toughness of aging bone. J Biomech 2011, 44:330-336.
42. Saito M., Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation of bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010, 21:195-214.
43. Schwartz A.V., Garnero P., Hillier T.A., Sellmeyer E.S., Feingold K., Resnick H.E., et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:2380-2386.
44. Manavalan J.S., Cremers S., Dempster D.W., Zhou H., Dworakowsky E., Kode A., et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:3240-3250.
45. Kawai M., de Paula F.J.A., Rosen C.J. New insights into osteoporosis: the bone-fat connection. J Intern Med 2012, 272:317-329.
46. Fazeli P.K., Horowitz M.C., MacDougald O.A., Scheller E.L., Rodeheffer M.S., Rosen C.J., et al. Marrow fat and bone-New perspectives. J Clin Endocrinol Metab 2013, 98:935-945.
47. Clements T., Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Min Res 2011, 26:677-680.
48. Yamamoto M., Yamaguchi T., Nawata K., Yamauchi M., Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1277-1284.
49. Naot D., Cornish J. Citokines and hormones that contribute to the positive association between fat and bone. Front Endocrinol 2014, 5:70. eCollection 2014.
50. Musso G., Paschetta E., Gambino R., Cassader M., Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med 2013, 19:522-535.
51. Högström M., Nordström A., Nordström P. Retinol, retinol-binding protein 4, abdominal fat mass, peak bone mineral density, and markers of bone metabolism in men: the northern osteoporosis and obesity (NO2) study. Eur J Endocrinol 2008, 158:765-770.
52. Gaudio A., Privitera F., Battaglia K., Troisi V., Sidoti M.H., Pulvirenti I., et al. Sclerostin levels associated with inhibition of the Wnt beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:3744-3750.
53. Gennari L., Merlotti D., Valenti R., Ceccarelli R., Ruvio M., Pietrini M.G., et al. Circulating sclerostin levels in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1737-1744.
54. Yamamoto M., Yamauchi M., Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:4030-4037.
55. Morales-Santana S., Garcia-Fontana B., Garcia-Martin A., Rozas-Moreno P., Garcia-Salced J.A., Reyes-Garcia R., et al. Atheroscleroic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013, 36:1667-1674.
56. Carnevale V., Inglese M., Annese M.A., De Matthaeis A., Santini S.A., Frusciante V., et al. Vitamin D and parameters of calcium homeostasis in inpatients with and without type 2 diabetes mellitus. J Endocrinol Invest 2012, 35:853-858.
57. Balducci S., Sacchetti M., Orlando G., Salvi L., Pugliese L., Salerno G., et al. Correlates of muscle strength in diabetes: the study on the assessment of determinants of muscle and bone strength abnormalities in diabetes (SAMBA). Nutr Metab Cardiovasc Dis 2014, 24:18-26. Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes SAMBA Investigators.
58. Muscogiuri G., Sorice G.P., Ajjan R., Mezza T., Pilz S., Prioletta A., et al. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr Metab Cardiovasc Dis 2012, 22:81-87.
59. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., et al. Effect of vitamin D on falls: a meta-analysis. J Am Med Assoc 2004, 291:1999-2006.
60. Gillespie L.D., Robertson M.C., Gillespie W.J., Sherrington C., Gates S., Clemson L.M., et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012 Sep 12, 2012:9. CD007146. 10.1002/14651858.
61. Montagnani A., Gonnelli S. Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 2013, 15:784-791.
62. Lipscombe L.L., Jamal S.A., Booth G.L., Hawker G.A. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007, 30:835-841.
63. Bilezikian J.P., Josse R.G., Eastell R., Lewiecki E.M., Miller C.G. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:1519-1528.
64. Lake Y.K., Singh S., Furberg C.D. Long-term Use Thiazolidinediones Fractures Type 2 Diabetes: A Meta-analysis. Can Med Assoc J 2009, 180:32-39.
65. Meier C., Kraenzlin M.E., Bodmer M., Jick S.S., Jick H., Meier C.R. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820-825.
66. Lapane K.L., Yang S., Brown M.J., Jawahar R., Pagliasotti C., Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging 2013, 30:527-547.
67. Yavopoulou M.P., Yovos J.G. Incretins and bone: evolving concepts in nutrient-dependent regulation o bone turnover. Hormones 2013, 12:214-223.
68. Monami M., Dicembrini I., Antenore A., Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures. Diabetes Care 2011, 34:2474-2476.
69. Vestergaard P., Rejnmark L., Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes?. Calcif Tissue Int 2011, 88:209-214.